Olverembatinib inhibits SARS‐CoV‐2‐Omicron variant‐mediated cytokine release in human peripheral blood mononuclear cells

The N‐terminus domain (NTD) of the SARS‐CoV‐2 Omicron variant spike protien strongly induces multiple inflammatory molecules in human peripheral blood mononuclear cells, unaffected by the mutations observed in the NTD. Olverembatinib, a clinical‐stage multi‐kinase inhibitor, potently inhibits Omicro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Marina, Holland, Eric C, Gujral, Taranjit S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174875/
https://www.ncbi.nlm.nih.gov/pubmed/35579119
http://dx.doi.org/10.15252/emmm.202215919
Descripción
Sumario:The N‐terminus domain (NTD) of the SARS‐CoV‐2 Omicron variant spike protien strongly induces multiple inflammatory molecules in human peripheral blood mononuclear cells, unaffected by the mutations observed in the NTD. Olverembatinib, a clinical‐stage multi‐kinase inhibitor, potently inhibits Omicron NTD‐mediated cytokine release.[Image: see text]

Ejemplares similares